Endothelin A receptor antagonists in congestive heart failure: Blocking the beast while leaving the beauty untouched?

Heart Failure Reviews

Volumn 6, Issue 4, 2001, Pages 301-315

  Spieker, Lukas E ^a   Noll, Georg ^a   Ruschitzka, Frank T ^a   Lüscher, Thomas F ^a  

^a UNIVERSITY HOSPITAL ZURICH   (Switzerland)

Author keywords

Arterial; Atherosclerosis; Endothelium; Hypertension; Myocardial infarction; Nitric oxide

Indexed keywords

2 [[2 [[2 [[(HEXAHYDRO 1H AZEPIN 1 YL)CARBONYL]AMINO] 4 METHYLPENTANOYL]AMINO] 3 (1 METHYL 1H INDOL 3 YL)PROPIONYL]AMINO] 3 (2 PYRIDYL)PROPIONIC ACID; 4 (4 METHOXYPHENYL) 2 (3,4 METHYLENEDIOXYPHENYL) 4 OXO 3 (3,4,5 TRIMETHOXYBENZYL) 2 BUTENOIC ACID; ATRASENTAN; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BIG ENDOTHELIN 1; BMS 193884; BOSENTAN; CYCLO(DEXTRO TRYPTOPHYL DEXTRO ASPARTYLPROLYL DEXTRO VALYLLEUCYL); DARUSENTAN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENDOTHELIN; ENDOTHELIN 1; ENDOTHELIN 2; ENDOTHELIN 3; ENDOTHELIN 4; ENDOTHELIN A RECEPTOR; ENDOTHELIN A RECEPTOR ANTAGONIST; ENDOTHELIN B RECEPTOR; ENDOTHELIN B RECEPTOR ANTAGONIST; N (2,6 DIMETHYLPIPERIDINOCARBONYL) 4 METHYLLEUCYL DEXTRO (1 METHOXYCARBONYLTRYPTOPHANYL) DEXTRO NORLEUCINE; NITRIC OXIDE; PROSTACYCLIN; RES 701 1; TAK 044; UNCLASSIFIED DRUG;

BLOOD VESSEL TONE; BRACHIAL ARTERY; CELL PROLIFERATION; CLINICAL TRIAL; CONGESTIVE HEART FAILURE; CORONARY ARTERY ATHEROSCLEROSIS; DOSE RESPONSE; DRUG EFFECT; DRUG INFUSION; DYSPNEA; EXERCISE TOLERANCE; HEART FUNCTION; HEART INFARCTION; HEART LEFT VENTRICLE FUNCTION; HEART MUSCLE ISCHEMIA; HEART OUTPUT; HEMODYNAMICS; HUMAN; HYPERTENSION; KIDNEY DISEASE; LUNG RECEPTOR; LUNG VASCULAR RESISTANCE; MORTALITY; NONHUMAN; PATHOPHYSIOLOGY; PLASMA CLEARANCE; PREDICTION; PROGNOSIS; PROTEIN BLOOD LEVEL; RECEPTOR INTRINSIC ACTIVITY; REVIEW; SYMPTOM; TREATMENT OUTCOME; VASCULAR DISEASE; VASCULAR RESISTANCE; VASOCONSTRICTION; VASODILATATION;

CORONARY CIRCULATION; ENDOTHELIN-1; HEART FAILURE, CONGESTIVE; HEMODYNAMIC PROCESSES; HUMANS; HYPERTENSION; MYOCARDIAL INFARCTION; RECEPTORS, ENDOTHELIN; TREATMENT OUTCOME; VASCULAR RESISTANCE;

EID: 0034908037     PISSN: 13824147     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1011456309039     Document Type: Review

References (224)

1. A novel potent vasoconstrictor peptide produced by vascular endothelial cells
2. Characterization of a coronary vasoconstrictor produced by cultured endothelial cells
3. Risk factors for heart failure in the general population: The study of men born in 1913
4. Epidemiology of heart failure in the United States
5. The epidemiology of heart failure: The Framingham study
6. The natural history of congestive heart failure: The Framingham study
7. Plasma endothelin in chronic heart failure
8. Increased plasma concentrations of endothelin in congestive heart failure in humans
9. Endothelin in human congestive heart failure
10. Comparison of plasma neurohormones in congestive heart failure patients with atrial fibrillation versus patients with sinus rhythm
11. Prognostic impact of big endothelin-1 plasma concentrations compared with invasive hemodynamic evaluation in severe heart failure
12. Phosphoramidon, a metalloproteinase inhibitor, suppresses the secretion of endothelin-1 from cultured endothelial cells by inhibiting a big endothelin-1 converting enzyme
13. Purification and characterization of endothelin-converting enzyme from rat lung
14. Purification and characterization of a phosphoramidon-sensitive endothelin-converting enzyme in porcine aortic endothelium
15. Cloning and functional expression of endothelin-converting enzyme from rat endothelial cells
16. The human preproendothelin-1 gene. Complete nucleotide sequence and regulation of expression
17. The human endothelin family: Three structurally and pharmacologically distinct isopeptides predicted by three separate genes
18. Immunological and structural characterization of sarafotoxin/endothelin family of peptides
19. Three apparent receptor subtypes for the endothelin/sarafotoxin family
20. Sarafotoxin, a novel vasoconstrictor peptide: Phosphoinositide hydrolysis in rat heart and brain
21. Release of endothelin from the porcine aorta. Inhibition of endothelium-derived nitric oxide
22. Oxidized low density lipoproteins induce mRNA expression and release of endothelin from human and porcine endothelium
23. Hemodynamic shear stress stimulates endothelin production by cultured endothelial cells
24. Hypoxia induces endothelin gene expression and secretion in cultured human endothelium
25. Acute pulmonary alveolar hypoxia increases lung and plasma endothelin-1 levels in conscious rats
26. Hypoxia increases endothelin release in bovine endothelial cells in culture, but epinephrine, norepinephrine, serotonin, histamine and angiotensin II do not
27. Production of endothelin by cultured porcine endothelial cells: Modulation by adrenaline
28. Cytokine-induced release of endothelin-1 from porcine renal epithelial cell line
29. Cytokine stimulated endothelin release from endothelial cells
30. Interleukin-2 enhances the release of endothelin-1 from the rat mesenteric artery
31. Cytokine and lipopolysaccharide stimulation of endothelin-1 release from human internal mammary artery and saphenous vein smooth-muscle cells
32. Endothelin stimulated by angiotensin II augments contractility of spontaneously hypertensive rat resistance arteries
33. Endothelin-1 release from endothelial cells in culture is elevated both acutely and chronically by short periods of mechanical stretch
34. Angiotensin II increases vascular and renal endothelin-1 and functional endothelin converting enzyme activity in vivo: Role of ETA receptors for endothelin regulation
35. Prolonged exercise causes an increase in endothelin-1 production in the heart in rats
36. Role of neutral endopeptidase in the metabolism of endothelin
37. Metabolism of endothelin-1 and big endothelin-1 by recombinant neutral endopeptidase EC.3.4.24.11
38. Endothelin is a potent mitogen for rat vascular smooth muscle cells
39. Cloning of a cDNA encoding a non-isopeptide-selective subtype of the endothelin receptor
40. Endothelin ETA and ETB receptors mediate vascular smooth muscle cell contraction
41. Both ETA and ETB receptors mediate contraction to endothelin-1 in human blood vessels
42. Cloning and expression of a cDNA encoding an endothelin receptor
43. Cloning and functional expression of a vascular smooth muscle endothelin 1 receptor
44. Human endothelin receptors characterized using reverse transcriptase-polymerase chain reaction, in situ hybridization, and subtyper-selective ligands BQ123 and BQ3020: Evidence for expression of ET(B) receptors in human vascular smooth muscle
45. The endothelin ET(B) receptor mediates both vasodilation and vasoconstriction in vivo
46. Endothelin ET(A) and ET(B) receptors cause vasoconstriction of human resistance and capacitance vessels in vivo
47. Endothelin-A receptor antagonist-mediated vasodilatation is attenuated by inhibition of nitric oxide synthesis and by endothelin-B receptor blockade
48. Pulmonary clearance of circulating endothelin-1 in dogs in vivo: Exclusive role of ETB receptors
49. Human pulmonary circulation is an important site for both clearance and production of endothelin-1
50. ETB-mediated regulation of extracellular levels of endothelin-1 in cultured human endothelial cells
51. Clearance of circulating endothelin-1 by ETB receptors in rats
52. Stimulation of endothelin mRNA and secretion in rat vascular smooth muscle cells: A novel autocrine function
53. Endothelin-1 as an autocrine growth factor for endothelial cells
54. Constitutive endothelin-1 overexpression promotes smooth muscle cell proliferation via an external autocrine loop
55. Endothelin receptor B subtype B mediates autoinduction of endothelin-1 in rat mesangial cells
56. Mobilization of intracellular calcium by endothelin in Swiss 3T3 cells
57. The calcium antagonist nifedipine inhibits arterial smooth muscle cell proliferation
58. Different mobilization of calcium in endothelin-1-induced contractions in human arteries and veins: Effects of calcium antagonists
59. Threshold concentrations of endothelin-1 potentiate contractions to norepinephrine and serotonin in human arteries. A new mechanism of vasospasm?
60. Endothelin-1-induced vasoconstriction in humans. Reversal by calcium channel blockade but not by nitrovasodilators or endothelium-derived relaxing factor
61. Endothelin and calcium antagonists in the skin microcirculation of patients with coronary artery disease
62. Polar secretion of endothelin-1 by cultured endothelial cells
63. Radio-immunoassay of endothelin in human plasma
64. Contribution of endogenous generation of endothelin-1 to basal vascular tone
65. Identification of endothelin receptors in cultured cerebellar neurons
66. Identification of endothelin receptors in various regions of rat brain
67. Regional hemodynamic and baroreflex effects of endothelin in rats
68. Regional and cardiac haemodynamic responses to glyceryl trmnitrate, acetylcholine, bradykinin and endothelin-1 in conscious rats: Effects of NG-nitro-L-arginine methyl ester
69. Different effects of low and high doses of endothelin on haemodynamics and hormones in the normotensive conscious dog
70. Cardiovascular and endocrine effects of endothelin-1 at pathophysiological and pharmacological plasma concentrations in conscious dogs
71. Central effects of endothelin on baroreflex of spontaneously hypertensive rats
72. Effects of centrally administered endothelin-3 on renal sympathetic nerve activity and renal blood flow in conscious rats
73. Suppression of baroreceptor discharge by endothelin at high carotid sinus pressure
74. Modulatory effects of endothelin on baroreflex activation in the nucleus of the solitary tract
75. Systemic and renal effect of intravenous infusion of endothelin-1 in healthy human volunteers
76. Aortic arch malformations and ventricular septal defect in mice deficient in endothelin-1
77. Transgenic expression of the endothelin-B receptor prevents congenital intestinal aganglionosis in a rat model of Hirschsprung disease
78. Targeted and natural (piebald-lethal) mutations of endothelin-B receptor gene produce megacolon associated with spotted coat color in mice
79. Interaction of endothelin-3 with endothelin-B receptor is essential for development of epidermal melanocytes and enteric neurons
80. A homozygous mutation in the endothelin-3 gene associated with a combined Waardenburg type 2 and Hirschsprung phenotype (Shah-Waardenburg syndrome)
81. Cranial and cardiac neural crest defects in endothelin-A receptor-deficient mice
82. The temporal requirement for endothelin receptor-B signalling during neural crest development
83. A potential role for endothelin-1 in human placental growth: Interactions with the insulin-like growth factor family of peptides
84. Role of blood pressure in the development of congestive heart failure. The Framingham study
85. The progression from hypertension to congestive heart failure
86. Indirect evidence for release of endothelium-derived relaxing factor in human forearm circulation in vivo. Blunted response in essential hypertension
87. Abnormal endothelium-dependent vascular relaxation in patients with essential hypertension
88. Imbalance of endothelium-derived relaxing and contracting factors. A new concept in hypertension?
89. Effect of endothelin-1 in man
90. Cardiopulmonary effects of endothelin-1 in man
91. ET-1 induces hypertrophy with enhanced expression of muscle specific genes in cultured neonatal rat cardiomyocytes
92. ET(A) receptor blockade prevents increased tissue endothelin-1, vascular hypertrophy, and endothelial dysfunction in salt-sensitive hypertension
93. Endothelin-1 potentiates smooth muscle cell growth to PDGF: Role of ETA and ETB receptor blockade
94. Left ventricular hypertrophy by electrocardiogram. Prevalence, incidence, and mortality in the Framingham study
95. Common carotid intima-media thickness and risk of stroke and myocardial infarction: The Rotterdam study
96. Carotid-artery intima and media thickness as a risk factor for myocardial infarction and stroke in older adults. Cardiovascular Health Study Collaborative Research Group
97. Vasoconstriction to endogenous endothelin-1 is increased in the peripheral circulation of patients with essential hypertension
98. Increased plasma endothelin level in patients with essential hypertension
99. Age- and sex-related variation of plasma endothelin-1 concentration in normal and hypertensive subjects
100. Bosentan in essential hypertension
101. Genetic variability of the ET-1 and the ETA receptor genes in essential hypertension
102. The Lys198Asn polymorphism in the endothelin-1 gene is associated with blood pressure in overweight people
103. Polymorphisms of the endothelin-A and -B receptor genes in relation to blood pressure and myocardial infarction: The Etude Cas-Temoins sur l'Infarctus du Myocarde (ECTIM) Study
104. Quantitative association between a newly identified molecular variant in the endothelin-2 gene and human essential hypertension
105. Chronic ETA receptor blockade attenuates cardiac hypertrophy independently of blood pressure effects in renovascular hypertensive rats
106. Angiotensin II increases tissue endothelin and induces vascular hypertrophy: Reversal by ET(A)-receptor antagonist
107. Effects of chronic ETA-receptor blockade in angiotensin II-induced hypertension
108. Blood pressure and vascular effects of endothelin blockade in chronic nitric oxide-deficient hypertension
109. The effect of an endothelin-receptor antagonist, bosentan, on blood pressure in patients with essential hypertension. Bosentan Hypertension Investigators
110. An overview of contemporary etiologies of congestive heart failure
111. Increased activation of sympathetic nervous system and endothelin by mental stress in normotensive offspring of hypertensive parents
112. Endothelin-1 inhibits nitric oxide synthesis in vascular smooth muscle cells
113. Effect of the endothelin family of peptides on human coronary artery smooth-muscle cell migration
114. Effect of endothelin-1 on neutrophil adhesion to endothelial cells and perfused heart
115. In vitro effect of endothelin-1 on collagen, and ADP-induced aggregation in human whole blood and platelet rich plasma
116. Flow-induced release of endothelium-derived relaxing factor
117. Interaction between endothelin-1 and endothelium-derived relaxing factor in human arteries and veins
118. Nitric oxide is responsible for flow-dependent dilatation of human peripheral conduit arteries in vivo
119. Enhanced secretion of endothelin-1 by elevated glucose levels from cultured bovine endothelial cells
120. Increased plasma endothelin-1 in heavy and light smokers
121. Circulating and tissue endothelin immunoreactivity in advanced atherosclerosis
122. Endothelin-1 and its mRNA in the wall layers of human arteries ex vivo
123. Plasma endothelin determination as a prognostic indicator of 1-year mortality after acute myocardial infarction
124. Acute hemodynamic and neurohumoral effects of selective ETA receptor blockade in patients with congestive heart failure
125. Endothelin-converting enzyme expression in the rat vascular injury model and human coronary atherosclerosis
126. Increased tissue endothelin immunoreactivity in atherosclerotic lesions associated with acute coronary syndromes
127. Tissue endothelin-1 immunoreactivity in the active coronary atherosclerotic plaque. A clue to the mechanism of increased vasoreactivity of the culprit lesion in unstable angina
128. Endothelin-1 and endothelin receptor mRNA expression in normal and atherosclerotic human arteries
129. TaqI polymorphism at the human preproendothelin-1 gene (EDN1)
130. TaqI identifies a four allele DNA polymorphism of the human endothelin-1 gene (EDN1)
131. A TaqI RFLP at the EDN1 gene locus
132. A short tandem repeat polymorphism at the endothelin 1 (EDN1) locus
133. Identification of a genetic risk factor for idiopathic dilated cardiomyopathy. Involvement of a polymorphism in the endothelin receptor type A gene. CARDIGENE group
134. Endothelin ETA receptor blockade restores NO-mediated endothelial function and inhibits atherosclerosis in apolipoprotein E-deficient mice
135. Chronic endothelin receptor antagonism preserves coronary endothelial function in experimental hypercholesterolemia
136. Hemodynamic and coronary effects of the endothelin antagonist bosentan in patients with coronary artery disease
137. Increased plasma concentrations of endothelin-1 and big endothelin-1 in acute myocardial infarction
138. Circulating endothelin in acute ischaemic syndromes
139. Plasma endothelin-1 in acute myocardial infarction with heart failure
140. Pharmacology of a non-selective ETA and ETB receptor antagonist, TAK-044 and the inhibition of myocardial infarct size in rats
141. Role of endogenous endothelin in the extension of myocardial infarct size studied with the endothelin receptor antagonist, TAK-044
142. Role of endogenous endothelin in extension of rabbit myocardial infarction
143. Contribution of endogenous endothelin to the extension of myocardial infarct size in rats
144. The endothelin-1 receptor antagonist BQ-123 reduces infarct size in a canine model of coronary occlusion and reperfusion
145. Inhibition of myocardial endothelin pathway improves long-term survival in heart failure
146. Concomitant endothelin receptor subtype-A blockade during the progression of pacing-induced congestive heart failure in rabbits. Beneficial effects on left ventricular and myocyte function
147. Role of endothelin in the maintenance of blood pressure in conscious rats with chronic heart failure. Acute effects of the endothelin receptor antagonist Ro 47-0203 (bosentan)
148. Direct evidence from intraneural recordings for increased central sympathetic outflow in patients with heart failure
149. Plasma norepinephrine as a guide to prognosis in patients with chronic congestive heart failure
150. Activity of the sympathetic nervous system and renin-angiotensin system assessed by plasma hormone levels and their relation to hemodynamic abnormalities in congestive heart failure
151. Altered production of endothelin-1 in the hypertrophied rat heart
152. Increased cardiac expression of endothelin-1 mRNA in ischemic heart failure in rats
153. Pulmonary hypertension caused by congestive heart failure is ameliorated by long-term application of an endothelin receptor antagonist. Increased expression of endothelin-1 messenger ribonucleic acid and endothelin-1-like immunoreactivity in the lung in congestive heart failure in rats
154. Increased cardiac and pulmonary endothelin-1 mRNA expression in canine pacing-induced heart failure
155. Coordinated upregulation of the cardiac endothelin system in a rat model of heart failure
156. Increased endothelin in experimental heart failure
157. Endogenous endothelin-1 participates in the maintenance of cardiac function in rats with congestive heart failure. Marked increase in endothelin-1 production in the failing heart
158. Plasma endothelin correlates with the extent of pulmonary hypertension in patients with chronic congestive heart failure
159. Plasma endothelin concentrations in humans with end-stage heart failure and after heart transplantation
160. Prognostic value of plasma soluble intercellular adhesion molecule-1 and endothelin-1 concentration in patients with chronic congestive heart failure
161. Expression of endothelin-1 and endothelin-converting enzyme-1 mRNAs and proteins in failing human hearts
162. Expression of endothelin-1, endothelin-converting enzyme, and endothelin receptors in chronic heart failure
163. Role of endothelin in the exercise intolerance of chronic heart failure
164. Plasma big endothelin-1 concentrations in congestive heart failure patients with or without systemic hypertension
165. Prognostic value of plasma endothelin-1 in patients with chronic heart failure
166. Value of cardiopulmonary exercise testing and big endothelin plasma levels to predict short-term prognosis of patients with chronic heart failure
167. Endothelin receptors in the failing and nonfailing human heart
168. Effect of endothelin-1 on exercise-induced vasodilation in normal subjects and in patients with heart failure
169. Venous endothelin receptor function in patients with chronic heart failure
170. Relation between endothelin-1 spillover in the lungs and pulmonary vascular resistance in patients with chronic heart failure
171. Plasma endothelin during upright tilt: Relevance for orthostatic hypotension?
172. Selective impairment of baroreflex-mediated vasoconstrictor responses in patients with ventricular dysfunction
173. Elevated endothelin-1 in heart failure and loss of normal response to postural change
174. Fluid flow decreases preproendothelin mRNA levels and suppresses endothelin-1 peptide release in cultured human endothelial cells
175. Modulation of NO and endothelin by chronic increases in blood flow in canine femoral arteries
176. Reduced pulmonary clearance of endothelin-1 contributes to the increase of circulating levels in heart failure secondary to myocardial infarction
177. Down-regulation of ET(B) receptor, but not ET(A) receptor, in congestive lung secondary to heart failure. Are marked increases in circulating endothelin-1 partly attributable to decreases in lung ET(B) receptor-mediated clearance of endothelin-1?
178. Elevated plasma endothelin concentrations in heart failure; An effect of angiotensin II?
179. Changes in plasma endothelin-1 levels reflect clinical response to beta-blockade in chronic heart failure
180. Plasma endothelin in congestive heart failure: Effect of the ACE inhibitor, fosinopril
181. Physical training improves endothelial function in patients with chronic heart failure
182. Effects of L-arginine on impaired acetylcholine-induced and ischemic vasodilation of the forearm in patients with heart failure
183. Isometric handgrip exercise increases endothelin-1 plasma levels in patients with chronic congestive heart failure
184. Elevated circulating levels of tumor necrosis factor in severe chronic heart failure
185. Increased concentrations of tumor necrosis factor in "chachectic" patients with severe chronic heart failure
186. Spontaneous endothelin production by circulating mononuclear cells from patients with chronic heart failure but not from normal subjects
187. Exogenous effects and endogenous production of endothelin in cardiac myocytes: Potential significance in heart failure
188. Contrasting inotropic effects of endogenous endothelin in the normal and failing human heart: Studies with an intracoronary ET(A) receptor antagonist
189. Comparison of the positive inotropic effects of serotonin, histamine, anglotensin II, endothelin and isoprenaline in the isolated human right atrium
190. Integrated cardiac, renal, and endocrine actions of endothelin
191. Endothelin stimulates aldosterone biosynthesis by dispersed rabbit adrenocapsular cells
192. Endothelin binding to cultured calf adrenal zona glomerulosa cells and stimulation of aldosterone secretion
193. Changes in plasma renin activity and aldosterone concentration in response to endothelin injection in dogs
194. Effects of endothelin on systemic and renal haemodynamics and neuroendocrine hormones in conscious dogs
195. Effects of endothelin on renal hemodynamics and excretory functions in anesthetized dogs
196. Mechanisms involved in the stimulation of aldosterone production by angiotensin II, vasopressin and endothelin
197. Endothelin receptor subtypes and stimulation of aldosterone secretion
198. Effects of enalapril on mortality in severe congestive heart failure. Results of the Cooperative North Scandinavian Enalapril Survival Group (CONSENSUS)
199. Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure
200. A randomized trial of β-blockade in heart failure: The cardiac insufficiency bisoprolol study (CIBIS)
201. Effect of metoprolol CR/XL in chronic heart failure: Metoprolol CR/XL Randomised Intervention Trial in Congestive Heart Failure (MERIT-HF)
202. Evidence for endothelin-1-mediated vasoconstriction in severe chronic heart failure
203. Short-term oral endothelin-receptor antagonist therapy in conventionally treated patients with symptomatic severe chronic heart failure
204. Pathophysiological role of endothelin revealed by the first orally active endothelin receptor antagonist
205. Reversal of postischemic acute renal failure with a selective endothelin A receptor antagonist in the rat
206. Bosentan improves renal regional blood flow in rats with experimental congestive heart failure
207. Systemic blockade of the endothelin-B receptor increases peripheral vascular resistance in healthy men
208. Comparison of the effects of selective endothelin ETA and ETB receptor antagonists in congestive heart failure
209. Endothelial function in chronic congestive heart failure
210. Flow-mediated arteriolar dilation is abnormal in congestive heart failure
211. Vasoconstrictor effect of endothelin-1 in human skin: Role of ETA and ETB receptors
212. Endothelin B receptors are functionally important in mediating vasoconstriction in the systemic circulation in patients with left ventricular systolic dysfunction
213. Upregulated expression of cardiac endothelin-1 participates in myocardial cell growth in Bio14.6 Syrian cardiomyopathic hamsters
214. Mild hypoxia induces hypertrophy of cultured neonatal rat cardiomyocytes: A possible role for endogenous endothelin-1-mediated mechanism
215. Angiotensin II stimulates cardiac myocyte hypertrophy via paracrine release of TGF-beta 1 and endothelin-1 from fibroblasts
216. Altered expression of isoforms of myosin heavy chain mRNA in the failing rat heart is ameliorated by chronic treatment with an endothelin receptor antagonist
217. Different secretion patterns of atrial natriuretic peptide and brain natriuretic peptide in patients with congestive heart failure
218. Comparison of the acute effects of a selective endothelin ETA and a mixed ETA/ETB receptor antagonist in heart failure
219. Beneficial effects of long-term selective endothelin type A receptor blockade in canine experimental heart failure
220. Chronic oral endothelin type A receptor antagonism in experimental heart failure
221. Short-term haemodynamic effects of BQ-123, a selective endothelin ET(A)-receptor antagonist, in chronic heart failure
222. Vasodilator effects of endothelin-converting enzyme inhibition and endothelin ETA receptor blockade in chronic heart failure patients treated with ACE inhibitors
223. Improved hemodynamics with the ET(A) selective receptor antagonist BMS-193884 in patients with heart failure